Open-Angle Glaucoma Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, China, UK, Germany - Size and Forecast 2024-2028

Open-Angle Glaucoma Therapeutics Market Size 2024-2028

The open-angle glaucoma therapeutics market size is forecast to increase by USD 2.36 billion at a CAGR of 6.1% between 2023 and 2028.

• The market is experiencing significant growth due to several key trends. Firstly, the promising pipeline and recent approvals for new glaucoma therapies are driving market expansion. Secondly, the development of biologic therapreutics for glaucoma treatment is gaining traction, offering potential for novel treatment options.
• Lastly, advances in glaucoma surgeries, including minimally invasive procedures, are improving patient outcomes and increasing the adoption of surgical interventions and surgical navigation systems. These trends are shaping the future of the market and providing opportunities for market participants. The market is expected to witness steady growth in the coming years, as these trends continue to shape the landscape and address the unmet needs of patients with open-angle glaucoma.

What will be the Size of the Open-Angle Glaucoma Therapeutics Market During the Forecast Period?

Request Free Sample

• The market caters to the development and provision of drugs and treatments for open-angle glaucoma, a leading cause of irreversible blindness worldwide. With an aging population, the prevalence of this optic nerve disorder is increasing, fueling market growth. Various drug classes, including topical eye drops like prostaglandins, beta blockers, alpha agonists, combination medication, carbonic anhydrase inhibitors, ALK inhibitors, and cholinergics, as well as prostaglandins analogs and oral medications, dominate the market.
• Intraocular pressure (IOP) reduction is the primary treatment goal. Topical eye drops remain the most common route of administration due to their ease of use and effectiveness. Laser therapy and surgery are alternative treatments for severe cases or when medication is insufficient.
• Ongoing research focuses on developing more effective and convenient treatment options for managing vision loss from open-angle glaucoma.

How is this Open-Angle Glaucoma Therapeutics Industry segmented and which is the largest segment?

The open-angle glaucoma therapeutics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

• Product
  • PGAs
  • Non-PGAs
• Channel
  • Hospital pharmacy
  • Retail pharmacy
  • Online pharmacy
• Geography
  • North America
    • Canada
    • US
  • Europe
    • Germany
    • UK
  • Asia
    • China
  • Rest of World (ROW)

By Product Insights

• The PGAs segment is estimated to witness significant growth during the forecast period.

Open-angle glaucoma, a leading cause of blindness among the elderly population, is managed primarily through various therapeutic options. Prostaglandin analogs (PGAs), such as bimatoprost (0.03%), latanoprost (0.005%), and travoprost (0.004%), are the first-line treatment for this condition. These topical eye drops are FDA-approved for reducing intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The mechanism of action for PGAs involves increasing aqueous humor outflow through the uveoscleral pathway, thereby lowering IOP. This effect may be attributed to the relaxation of the ciliary muscle and potential remodeling of the extracellular matrix elements. Combination medication, including PGAs and beta blockers or carbonic anhydrase inhibitors, offers increased efficacy compared to monotherapy.

Diabetes is a significant risk factor for open-angle glaucoma, and healthcare spending on glaucoma therapeutics and medical diagnostics continues to rise. Intraocular pressure management is crucial in preventing vision loss, and various treatment modalities, including medication, laser therapy, and surgery, are available. Intraocular pressure reduction is essential for managing optic nerve damage and preserving vision.

Get a glance at the Open-Angle Glaucoma Therapeutics Industry report of share of various segments Request Free Sample

The PGAs segment was valued at USD 3.09 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

• North America is estimated to contribute 51% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

Open-angle glaucoma, the most common form of this eye condition, affects approximately three million Americans, making North America a significant market for therapeutics. According to the Centers for Disease Control and Prevention (CDC), risk factors include African Americans over 40, individuals over 60, those with a family history, and people with diabetes, who are two times more likely to develop glaucoma. This condition, the second leading cause of blindness globally, often presents without early symptoms, affecting around 50% of diagnosed cases. The disease results from increased intraocular pressure due to a malfunctioning outflow system in the eye, damaging the optic nerve and leading to vision loss.

Various drug classes, including alpha-adrenergic agonists, hyperosmotics, beta blockers, carbonic anhydrase inhibitors, and prostaglandins, are used for treatment via topical eye drops, oral medications, injections, and laser therapy. Intraocular pressure reduction is the primary goal, targeting the trabecular meshwork and aqueous humor. Diagnostic tools, such as visual field testing, are essential for early detection and treatment. The high treatment costs, driven by advanced medical technologies and specialty clinics, are a significant challenge for the healthcare industry. The patient pool continues to expand, with the elderly population and those with diabetes being key demographics. The medical device industries and healthcare expenditure are expected to grow alongside the increasing need for glaucoma therapeutics.

Market Dynamics

Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

What are the key market drivers leading to the rise In the adoption of Open-Angle Glaucoma Therapeutics Industry?

Promising pipeline and recent approvals for glaucoma therapies is the key driver of the market.

• Open-angle glaucoma, a leading cause of blindness among the elderly population In the US, has driven significant investment In the development of new therapeutics. In recent developments, the Food and Drug Administration (FDA) has approved several new drugs for the treatment of open-angle glaucoma. For instance, in October 2022, Santen Pharmaceutical received approval for OMLONTI, an ophthalmic solution containing 0.002% omidenepag isopropyl, which lowers intraocular pressure (IOP) in individuals with ocular hypertension or open-angle glaucoma. Similarly, in April 2021, Bausch and Lomb, an international ophthalmology company, secured approval from the Brazilian Health Regulatory Agency (ANVISA) for VYZULTA (latanoprostene bunod ophthalmic solution), 0.024%,
• which also reduces IOP. These new drugs join a growing list of treatments for open-angle glaucoma, which includes alpha-adrenergic agonists, hyperosmotics, beta blockers, carbonic anhydrase inhibitors, oral drugs, and topical eye drops such as prostaglandins, alpha agonists, and prostaglandin analogs. The market for open-angle glaucoma therapeutics is expected to grow due to the increasing patient pool and healthcare spending. However, high treatment costs remain a challenge, with advanced medical technologies and targeted therapies adding to the expense. Diabetes, an underlying condition that increases the risk of open-angle glaucoma, also contributes to healthcare expenditure. Diagnostic tools like visual field testing and laser therapy, as well as surgical options such as trabeculectomy and intraocular pressure (IOP) lowering injections, are also used In the treatment of open-angle glaucoma.
• The market for open-angle glaucoma therapeutics is dynamic, with ongoing research and development efforts aimed at improving treatment outcomes and reducing the burden of this sight-threatening condition.

What are the market trends shaping the Open-Angle Glaucoma Therapeutics Industry?

Development of biologics for glaucoma treatment is the upcoming market trend.

• Open-angle glaucoma, a leading cause of blindness among the elderly population in the US, is characterized by optic nerve damage and vision loss due to increased intraocular pressure (IOP). Current treatment options primarily consist of small molecule drugs, such as alpha-adrenergic agonists, hyperosmotics, beta blockers, carbonic anhydrase inhibitors, prostaglandins, and combination medication. These drugs are administered through topical eye drops or oral medications, aiming to reduce IOP by enhancing the outflow of aqueous humor or decreasing its production. However, these treatments come with side effects and challenges, including patient non-adherence and high costs. To address these challenges, the biopharmaceutical industry is exploring novel treatments for open-angle glaucoma.
• Biologics, such as antisense oligonucleotides, are under development to offer improved safety and efficacy over small molecules. For instance, Isarna Therapeutics is developing ISTH0036, an antisense oqugnoleotide targeting TGF-beta 2, a key player in open-angle glaucoma pathogenesis. The unmet medical needs In the market are significant, given the increasing prevalence of ocular disorders, including diabetes-related diabetic retinopathy, and the associated healthcare spending. The market dynamics are influenced by factors such as the growing patient pool, advancements in medical technologies, and the rising demand for targeted therapies. Despite the high treatment costs, specialized clinics and medical device industries are investing in advanced medical technologies to improve patient outcomes and reduce the burden of vision loss.

What challenges does the Open-Angle Glaucoma Therapeutics Industry face during its growth?

Advances in glaucoma surgeries is a key challenge affecting the industry growth.

• Open-angle glaucoma is a leading cause of blindness among the elderly population In the US, characterized by optic nerve damage and vision loss due to increased intraocular pressure (IOP). Various drug classes, including alpha-adrenergic agonists, hyperosmotics, beta blockers, carbonic anhydrase inhibitors, and prostaglandins, are used as topical eye drops to reduce IOP. However, these drugs may have side effects, such as stinging or redness of the eyes, and require patient adherence, which can be challenging due to their high cost. To address these limitations, alternative treatment options, such as devices and surgery, have emerged. For instance, Trabeculectomy, a traditional surgical method, and laser trabeculoplasty are used when medical therapy fails to control IOP and prevent optic nerve damage.
• Furthermore, the development of advanced medical technologies, such as targeted therapies and diagnostic tools like visual field testing, has improved the effectiveness and accessibility of glaucoma treatment. The healthcare spending on eye diseases, including glaucoma, is expected to increase due to the growing elderly population and the high treatment costs. The market for open-angle glaucoma therapeutics includes various medication classes, such as oral drugs, injections, and combination medication, like cholinergics and prostaglandin analogs. These medications target different mechanisms to reduce IOP, such as decreasing the production of aqueous humor or increasing its outflow through the trabecular meshwork. Diabetes, a significant risk factor for glaucoma, also influences the market dynamics, as patients with diabetic retinopathy often require specialized care in specialty clinics.
• The use of intraocular pressure-lowering medications and laser therapy is common in managing glaucoma in diabetic patients. Intraocular pressure-lowering medications include beta-blockers, prostaglandin analogs, and carbonic anhydrase inhibitors, which are administered through various routes, such as allergy relieving eye drops, oral medications, and injections. In conclusion, the market is a critical segment of the healthcare industry, driven by the increasing prevalence of the disease, the growing elderly population, and the need for effective and accessible treatment options. The market includes various drug classes, devices, and surgical methods, each with its advantages and limitations. The high treatment costs and the importance of patient adherence necessitate ongoing research and development to improve the efficacy, safety, and affordability of glaucoma therapies.

Exclusive Customer Landscape

The open-angle glaucoma therapeutics market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the open-angle glaucoma therapeutics market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, open-angle glaucoma therapeutics market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence In the industry.

The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• AbbVie Inc.
• Alcon Inc.
• Bausch Health Companies Inc.
• Hikma Pharmaceuticals Plc
• Inotek Pharmaceuticals
• Merck and Co. Inc.
• Nicox S.A.
• Novartis AG
• Otsuka Pharmaceutical Co. Ltd.
• Pfizer Inc.
• Santen Pharmaceutical Co. Ltd.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Research Analyst Overview

Open-angle glaucoma is a leading cause of irreversible vision loss and blindness, particularly among the elderly population. This ocular disorder is characterized by an increase in intraocular pressure (IOP), which damages the optic nerve and the retina, leading to vision loss. The market for therapeutics to treat open-angle glaucoma is significant, driven by the growing elderly population, increasing healthcare spending, and the high treatment costs associated with this condition. The primary goal of open-angle glaucoma therapeutics is to reduce IOP and prevent further vision loss. Various drug classes have been developed to achieve this objective, including alpha-adrenergic agonists, hyperosmotics, beta-blockers, carbonic anhydrase inhibitors, oral drugs, and topical eye drops.

Alpha agonists work by decreasing the production of aqueous humor In the eye, thereby reducing IOP. Hyperosmotics draw water from the eye, also decreasing aqueous humor production and IOP. Beta-blockers, on the other hand, reduce IOP by decreasing the production of aqueous humor and increasing its outflow. Carbonic anhydrase inhibitors decrease aqueous humor production by inhibiting the enzyme carbonic anhydrase. Oral medications, such as beta-blockers and carbonic anhydrase inhibitors, are often prescribed for open-angle glaucoma patients who cannot tolerate or are unresponsive to topical eye drops. However, these oral medications come with the risk of side effects, including diabetes, and can be expensive.

Topical eye drops, including prostaglandins, alpha agonists, and prostaglandin analogs, are the most commonly prescribed treatment for open-angle glaucoma. Prostaglandins increase the outflow of aqueous humor from the eye, reducing IOP. Alpha agonists and prostaglandin analogs also decrease aqueous humor production. Combination medication, which involves the use of multiple drug classes in a single formulation, is another therapeutic option for open-angle glaucoma patients. Cholinergics, which decrease aqueous humor production, are sometimes used in combination with beta-blockers or prostaglandin analogs. Laser therapy and surgery are also used to treat open-angle glaucoma when medication is insufficient. Laser therapy, including selective laser trabeculoplasty and laser iridotomy, increases the outflow of aqueous humor from the eye.

Surgery, such as trabeculectomy and drainage implants, physically alters the drainage system of the eye to improve aqueous humor outflow. Diagnostic tools, including visual field testing and tonometry, are essential for the accurate diagnosis and monitoring of open-angle glaucoma. Advanced medical technologies, such as optical coherence tomography and confocal scanning laser ophthalmoscopy, provide additional diagnostic information and can help guide treatment decisions. The high treatment costs associated with open-angle glaucoma, coupled with the increasing prevalence of this condition, make it a significant market for therapeutics. The patient pool for open-angle glaucoma is expected to grow as the population ages, and the medical device industries are investing in research and development to create new medical technologies.

In conclusion, open-angle glaucoma is a leading cause of vision loss and blindness, particularly among the elderly population. The market for therapeutics to treat this condition is significant, driven by the growing elderly population, increasing healthcare spending, and the high treatment costs associated with this condition. Various drug classes, including alpha-adrenergic agonists, hyperosmotics, beta-blockers, carbonic anhydrase inhibitors, oral drugs, and topical eye drops, are used to reduce IOP and prevent further vision loss. Laser therapy and surgery are also used when medication is insufficient. Diagnostic tools are essential for accurate diagnosis and monitoring, and advanced medical technologies provide additional diagnostic information and guide treatment decisions. The market for open-angle glaucoma therapeutics is expected to grow as the population ages and new and innovative treatments are developed.

Request Free Sample

What are the Key Data Covered in this Open-Angle Glaucoma Therapeutics Market Research and Growth Report?

• CAGR of the Open-Angle Glaucoma Therapeutics industry during the forecast period
• Detailed information on factors that will drive the growth and forecasting between 2024 and 2028
• Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
• Accurate predictions about upcoming growth and trends and changes in consumer behaviour
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market's competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the open-angle glaucoma therapeutics market growth of industry companies

We can help! Our analysts can customize this open-angle glaucoma therapeutics market research report to meet your requirements.

Get in touch